search
Back to results

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults (VISION-1)

Primary Purpose

Presbyopia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Pilocarpine Ophthalmic
Placebo
Sponsored by
Eyenovia Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Presbyopia

Eligibility Criteria

40 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Primary Inclusion Criteria:

  • Poor near vision impacting daily living that requires near correction
  • Best-corrected distance visual acuity (BCDVA) of 0.0 logMar or better
  • Manifest refraction spherical equivalent ≥ -2.00 Diopters (D) and ≤ +2.00 D
  • Monocular DCNVA between 0.4 and 0.7 logMAR, inclusive

Primary Exclusion Criteria:

  • Diagnosis of glaucoma or ocular hypertension
  • Narrow iridocorneal angles
  • History of intraocular surgery, refractive surgery, laser treatment, or iris surgery
  • Clinically significant abnormality of cornea, lens, retina, ciliary body, or iris
  • Presence/history of a severe/serious ocular condition or any other unstable medical condition
  • Presence or history of manifest strabismus, amblyopia, or nystagmus
  • Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye syndrome managed using artificial tears
  • Clinically significant external ocular inflammation within 30 days of Screening Visit
  • Current use or history of rigid gas permeable (RGP) contact lens use within 30 days of Screening Visit
  • Known pilocarpine allergy or contraindication to use of pilocarpine
  • Presence or history of congenital heart anomaly, valve disease, or other cardiac disease
  • Disabling arthritis or limited motor coordination that would limit the subject's ability to self-administer study solution using the Optejet

Sites / Locations

  • VISION-1 Study Site #21
  • VISION-1 Study Site #52
  • VISION-1 Study Site #54
  • VISION-1 Study Site #53
  • VISION-1 Study Site #50
  • VISION-1 Study Site #17
  • VISION-1 Study Site #22
  • VISION-1 Study Site #51
  • VISION-1 Study Site #03

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Pilocarpine 1% Solution

Pilocarpine 2% Solution

Placebo Solution

Arm Description

1% pilocarpine ophthalmic solution administered with the Optejet dispenser

2% pilocarpine ophthalmic solution administered with the Optejet dispenser

Placebo ophthalmic solution administered with the Optejet dispenser

Outcomes

Primary Outcome Measures

Proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA)
The proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular DCNVA as compared to baseline.

Secondary Outcome Measures

Full Information

First Posted
December 1, 2020
Last Updated
August 5, 2021
Sponsor
Eyenovia Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04657172
Brief Title
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
Acronym
VISION-1
Official Title
A Phase 3 Study of the Safety and Efficacy of 1% and 2% Pilocarpine Ophthalmic Solutions Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
December 15, 2020 (Actual)
Primary Completion Date
March 26, 2021 (Actual)
Study Completion Date
March 26, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eyenovia Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting study inclusion/exclusion criteria are scheduled for 3 treatment visits. At each treatment visit, 1 of the 3 study solutions is self-administered to both eyes. Afterwards, efficacy and safety assessments are performed over a 3-hour period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Presbyopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pilocarpine 1% Solution
Arm Type
Experimental
Arm Description
1% pilocarpine ophthalmic solution administered with the Optejet dispenser
Arm Title
Pilocarpine 2% Solution
Arm Type
Experimental
Arm Description
2% pilocarpine ophthalmic solution administered with the Optejet dispenser
Arm Title
Placebo Solution
Arm Type
Placebo Comparator
Arm Description
Placebo ophthalmic solution administered with the Optejet dispenser
Intervention Type
Drug
Intervention Name(s)
Pilocarpine Ophthalmic
Other Intervention Name(s)
MicroLine
Intervention Description
Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Vehicle ophthalmic solution administered with the Optejet microdose dispenser
Primary Outcome Measure Information:
Title
Proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA)
Description
The proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular DCNVA as compared to baseline.
Time Frame
120 minutes post-dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Primary Inclusion Criteria: Poor near vision impacting daily living that requires near correction Best-corrected distance visual acuity (BCDVA) of 0.0 logMar or better Manifest refraction spherical equivalent ≥ -2.00 Diopters (D) and ≤ +2.00 D Monocular DCNVA between 0.4 and 0.7 logMAR, inclusive Primary Exclusion Criteria: Diagnosis of glaucoma or ocular hypertension Narrow iridocorneal angles History of intraocular surgery, refractive surgery, laser treatment, or iris surgery Clinically significant abnormality of cornea, lens, retina, ciliary body, or iris Presence/history of a severe/serious ocular condition or any other unstable medical condition Presence or history of manifest strabismus, amblyopia, or nystagmus Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye syndrome managed using artificial tears Clinically significant external ocular inflammation within 30 days of Screening Visit Current use or history of rigid gas permeable (RGP) contact lens use within 30 days of Screening Visit Known pilocarpine allergy or contraindication to use of pilocarpine Presence or history of congenital heart anomaly, valve disease, or other cardiac disease Disabling arthritis or limited motor coordination that would limit the subject's ability to self-administer study solution using the Optejet
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tsontcho (Sean) Ianchulev, MD, MPH
Organizational Affiliation
Eyenovia Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
VISION-1 Study Site #21
City
Azusa
State/Province
California
ZIP/Postal Code
91702
Country
United States
Facility Name
VISION-1 Study Site #52
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Facility Name
VISION-1 Study Site #54
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80528
Country
United States
Facility Name
VISION-1 Study Site #53
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
VISION-1 Study Site #50
City
New York
State/Province
New York
ZIP/Postal Code
10036
Country
United States
Facility Name
VISION-1 Study Site #17
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
VISION-1 Study Site #22
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27603
Country
United States
Facility Name
VISION-1 Study Site #51
City
Cranberry Township
State/Province
Pennsylvania
ZIP/Postal Code
16066
Country
United States
Facility Name
VISION-1 Study Site #03
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

We'll reach out to this number within 24 hrs